Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allakos Inc.ALLK · Entity 79644 | member - potential 10% group | March 03, 2021 | March 06, 2021 |
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | Director | May 30, 2019 | June 03, 2019 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director | May 28, 2026 | June 01, 2026 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | August 11, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allakos Inc.
Report date March 03, 2021 · Filed March 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,154 |
Reported balance
After 2021-03-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-03-03 · Sale · Disposed 400 · Balance 32,154 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.24 - $111.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F4: Shares held prior to the reported transaction consisted of 32,554 shares received in a pro rata distribution from APNG I subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16. |
| Common StockSEC Table I · non-derivative | Direct | 30,254 |
Reported balance
After 2021-03-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2021-03-03 · Sale · Disposed 1,900 · Balance 30,254 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.265 - $112.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 29,954 |
Reported balance
After 2021-03-03 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2021-03-03 · Sale · Disposed 300 · Balance 29,954 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 - $112.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 29,554 |
Reported balance
After 2021-03-03 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2021-03-03 · Sale · Disposed 400 · Balance 29,554 F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.38 - $114.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 27,676 |
Reported balance
After 2021-03-03 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2021-03-03 · Sale · Disposed 1,878 · Balance 27,676 F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.005 - $115.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 26,576 |
Reported balance
After 2021-03-04 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2021-03-04 · Sale · Disposed 1,100 · Balance 26,576 F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.09 - $108.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 23,780 |
Reported balance
After 2021-03-04 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2021-03-04 · Sale · Disposed 2,796 · Balance 23,780 F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.09 - $110.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 21,970 |
Reported balance
After 2021-03-04 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2021-03-04 · Sale · Disposed 1,810 · Balance 21,970 F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 - $111.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 18,690 |
Reported balance
After 2021-03-04 transaction · row 10
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 10 · 2021-03-04 · Sale · Disposed 3,280 · Balance 18,690 F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.43 - $112.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 12,776 |
Reported balance
After 2021-03-04 transaction · row 11
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 11 · 2021-03-04 · Sale · Disposed 5,914 · Balance 12,776 F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.54 - $113.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 12,676 |
Reported balance
After 2021-03-04 transaction · row 12
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 12 · 2021-03-04 · Sale · Disposed 100 · Balance 12,676 |
| Common StockSEC Table I · non-derivative | Direct | 10,076 |
Reported balance
After 2021-03-05 transaction · row 13
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 13 · 2021-03-05 · Sale · Disposed 2,600 · Balance 10,076 F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.25 - $116.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 6,205 |
Reported balance
After 2021-03-05 transaction · row 14
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 14 · 2021-03-05 · Sale · Disposed 3,871 · Balance 6,205 F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.25 - $117.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 4,505 |
Reported balance
After 2021-03-05 transaction · row 15
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 15 · 2021-03-05 · Sale · Disposed 1,700 · Balance 4,505 F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.27 - $118.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 3,205 |
Reported balance
After 2021-03-05 transaction · row 16
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 16 · 2021-03-05 · Sale · Disposed 1,300 · Balance 3,205 F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.27 - $119.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 1,605 |
Reported balance
After 2021-03-05 transaction · row 17
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 17 · 2021-03-05 · Sale · Disposed 1,600 · Balance 1,605 F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.29 - $120.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 605 |
Reported balance
After 2021-03-05 transaction · row 18
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 18 · 2021-03-05 · Sale · Disposed 1,000 · Balance 605 F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.53 - $121.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-05 transaction · row 19
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 19 · 2021-03-05 · Sale · Disposed 605 · Balance 0 F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.60 - $122.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,071,147 |
Reported balance
Holding disclosure · report date 2021-03-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,071,147 F1: Reflects a distribution in kind effected by Alta Partners NextGen Fund I L.P. ("APNG I") subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16. F2: These shares are directly held by APNG I. Alta Partners NextGen Fund I Management, LLC ("APNG I Management") is the general partner of APNG I. The Reporting Person is one of three managing directors of APNG I Management and, as such, has voting and investment control with respect to the shares held by APNG I. The Reporting Person disclaims beneficial ownership of all shares held by APNG I, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a distribution in kind effected by Alta Partners NextGen Fund I L.P. ("APNG I") subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16.
F2: These shares are directly held by APNG I. Alta Partners NextGen Fund I Management, LLC ("APNG I Management") is the general partner of APNG I. The Reporting Person is one of three managing directors of APNG I Management and, as such, has voting and investment control with respect to the shares held by APNG I. The Reporting Person disclaims beneficial ownership of all shares held by APNG I, except to the extent of his pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.24 - $111.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4: Shares held prior to the reported transaction consisted of 32,554 shares received in a pro rata distribution from APNG I subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.265 - $112.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 - $112.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.38 - $114.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.005 - $115.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.09 - $108.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.09 - $110.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 - $111.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.43 - $112.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.54 - $113.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.25 - $116.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.25 - $117.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.27 - $118.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.27 - $119.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.29 - $120.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.53 - $121.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.60 - $122.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Sienna Biopharmaceuticals, Inc.
Report date May 30, 2019 · Filed June 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2029-05-30 | Direct | 25,000 |
Reported balance
After 2019-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date.
Tyra Biosciences, Inc.
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.68 · Expires 2036-05-27 | Direct | 13,160 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 13,160 · Balance 13,160 F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Vir Biotechnology, Inc.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,656 |
Reported balance
After 2026-08-11 transaction · row 1
1 source rowRow 1 · 2026-08-11 · Other · Disposed 8,000 · Balance 40,656 F1: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 517,917 |
Reported balance
After 2026-08-11 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-11 · Other · Acquired 8,000 · Balance 517,917 F1: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards. F2: The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards.
F2: The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 5,914 | $113.03 | $668,459.42 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 11 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,776 F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.54 - $113.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 04, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 3,280 | $111.92 | $367,097.60 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 10 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,690 F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.43 - $112.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 04, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 1,810 | $110.63 | $200,240.30 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 9 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,970 F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 - $111.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 04, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 2,796 | $109.72 | $306,777.12 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 8 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,780 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.09 - $110.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 04, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 1,100 | $108.36 | $119,196.00 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 7 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,576 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.09 - $108.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 1,878 | $115.22 | $216,383.16 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 6 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,676 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.005 - $115.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 400 | $113.75 | $45,500.00 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 5 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,554 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.38 - $114.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 300 | $112.59 | $33,777.00 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 4 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,954 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 - $112.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 1,900 | $111.62 | $212,078.00 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 3 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,254 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.265 - $112.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 00:42 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 400 | $110.89 | $44,356.00 |
DisclosureSEC source: 0001209191-21-018405 · doc4.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,154 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.24 - $111.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F4 · balance_after: Shares held prior to the reported transaction consisted of 32,554 shares received in a pro rata distribution from APNG I subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 28,888 | $0.00 Strike: $37.06 | $0.00 |
DisclosureSEC source: 0001209191-20-032065 · doc4.xml · derivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,888 Underlying: Common Stock · 28,888 shares Expires 2030-05-21 Read SEC document |
| May 21, 2020 Filed Oct 13, 2020 23:11 UTC Amendment | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 24,355 | $0.00 Strike: $37.06 | $0.00 |
DisclosureSEC source: 0001209191-20-054737 · doc4a.xml · derivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,355 Underlying: Common Stock · 24,355 shares Expires 2030-05-20 Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:08 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 600 | $72.74 | $43,644.00 |
DisclosureSEC source: 0001209191-20-031002 · doc4.xml · nonDerivative · entry 3 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.72 - $72.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:08 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 4,506 | $72.25 | $325,558.50 |
DisclosureSEC source: 0001209191-20-031002 · doc4.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.68 - $72.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:08 UTC | Allakos Inc. ALLK · Entity 79644 | SaleCommon Stock | 6,432 | $71.01 | $456,736.32 |
DisclosureSEC source: 0001209191-20-031002 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · member - potential 10% group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,106 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.46 - $71.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 01, 2020 Filed May 5, 2020 21:55 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,700 | $28.60 | $77,212.44 |
DisclosureSEC source: 0001209191-20-027256 · doc4.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,534 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.51 to $28.675, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 01, 2020 Filed May 5, 2020 21:55 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 15,758 | $27.90 | $439,640.32 |
DisclosureSEC source: 0001209191-20-027256 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,234 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.51 to $28.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F2 · balance_after: Includes an estimated 29,170 shares received in a pro-rata distribution from Alta Partners NextGen Fund I, L.P. (APNG 1) initiated on April 29, 2020. The reporting person will file an amendment to this Form 4 if the final number of shares received by him in the distribution changes from the amount reported herein. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:24 UTC | Allakos Inc. ALLK · Entity 79644 | OtherCommon Stock | 6,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 7 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,837 F9 · kind: Represents the acquisition of the shares of Common Stock of the Issuer by Guy P. Nohra in connection with the pro-rata distribution described in footnote (1) herein. F9 · ownership.direct: Represents the acquisition of the shares of Common Stock of the Issuer by Guy P. Nohra in connection with the pro-rata distribution described in footnote (1) herein. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:24 UTC | Allakos Inc. ALLK · Entity 79644 | OtherCommon Stock | 11,539 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 6 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alta Bioequities, L.P. Disclosed balance after: 11,539 F8 · kind: Represents the acquisition of the shares of Common Stock of the Issuer by Alta Bioequities, L.P. in connection with the pro-rata distribution described in footnote (5) herein. Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. F8 · ownership.nature: Represents the acquisition of the shares of Common Stock of the Issuer by Alta Bioequities, L.P. in connection with the pro-rata distribution described in footnote (5) herein. Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:24 UTC | Allakos Inc. ALLK · Entity 79644 | OtherCommon Stock | 11,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 5 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hudson Capital LLC Disclosed balance after: 11,538 F7 · kind: Represents the acquisition of the shares of Common Stock of the Issuer by Hudson Capital, LLC, a limited liability company of which Peter A. Hudson is the managing member, in connection with the pro-rata distribution described in footnote (5) herein. Mr. Hudson disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. F7 · ownership.nature: Represents the acquisition of the shares of Common Stock of the Issuer by Hudson Capital, LLC, a limited liability company of which Peter A. Hudson is the managing member, in connection with the pro-rata distribution described in footnote (5) herein. Mr. Hudson disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:24 UTC | Allakos Inc. ALLK · Entity 79644 | OtherCommon Stock | 11,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 4 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 F6 · kind: Represents the acquisition of the shares of Common Stock of the Issuer by Robert J. More in connection with the pro-rata distribution described in footnote (5) herein. F6 · ownership.direct: Represents the acquisition of the shares of Common Stock of the Issuer by Robert J. More in connection with the pro-rata distribution described in footnote (5) herein. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:24 UTC | Allakos Inc. ALLK · Entity 79644 | OtherCommon Stock | 34,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 3 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By APNG I Management Disclosed balance after: 0 F5 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by APNG I Management, without consideration, to its members. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:24 UTC | Allakos Inc. ALLK · Entity 79644 | OtherCommon Stock | 34,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 2 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By APNG I Management Disclosed balance after: 34,615 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners NextGen Fund I L.P. ("APNG I"), without consideration, to its general partner and limited partners. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:24 UTC | Allakos Inc. ALLK · Entity 79644 | OtherCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 1 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,519,200 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners NextGen Fund I L.P. ("APNG I"), without consideration, to its general partner and limited partners. F2 · ownership.nature: Consists of 2,557,377 shares held of record by APNG I and 7,961,823 shares held of record by Alta Partners VIII, L.P. ("Alta VIII"). F3 · ownership.nature: The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their respective pecuniary interests therein. F4 · ownership.nature: The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC ("APNG I Management"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries B Convertible Preferred Stock · Derivative | 277,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053662 · doc4.xml · derivative · entry 5 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 277,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by Alta Partners NextGen Fund I, L.P. (APNG 1). The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 60,822 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053662 · doc4.xml · derivative · entry 4 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,822 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 1,666,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053662 · doc4.xml · derivative · entry 3 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,666,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by Alta Partners NextGen Fund I, L.P. (APNG 1). The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 60,822 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053662 · doc4.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 1,944,443 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053662 · doc4.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,944,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by Alta Partners NextGen Fund I, L.P. (APNG 1). The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 19:38 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 25,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001562180-19-003242 · primarydocument.xml · derivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-30 F1 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 17:16 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | PurchaseCommon Stock | 100,000 | $2.50 | $250,000.00 |
DisclosureSEC source: 0001562180-19-001424 · primarydocument.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,942 F1 · kind: The Reporting Person purchased the shares of the Issuer's common stock in connection with the Issuer's public offering at the offering price of $2.50 per share. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 17:01 UTC | Allakos Inc. ALLK · Entity 79644 | ConversionSeries B Preferred Stock · Derivative | 1,239,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-043627 · doc4.xml · derivative · entry 4 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,239,007 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2 · derivative.exercise_date: The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2 · derivative.expiration_date: The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F4 · ownership.nature: The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. F5 · ownership.nature: The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC ("APNG I Management"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their pecuniary interests therein. F8 · ownership.nature: APNG I owns 504,547 shares of Series B Preferred Stock. Alta VIII owns 734,460 shares of Series B Preferred Stock. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 17:01 UTC | Allakos Inc. ALLK · Entity 79644 | ConversionSeries A Preferred Stock · Derivative | 10,030,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-043627 · doc4.xml · derivative · entry 3 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 10,030,193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F4 · ownership.nature: The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. F5 · ownership.nature: The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC ("APNG I Management"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their pecuniary interests therein. F7 · ownership.nature: APNG I owns 2,941,718 shares of Series A Preferred Stock. Alta VIII owns 7,088,475 shares of Series A Preferred Stock. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 17:01 UTC | Allakos Inc. ALLK · Entity 79644 | PurchaseCommon Stock | 250,000 | $18.00 | $4,500,000.00 |
DisclosureSEC source: 0001209191-18-043627 · doc4.xml · nonDerivative · entry 2 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,519,200 F4 · ownership.nature: The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. F5 · ownership.nature: The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC ("APNG I Management"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their pecuniary interests therein. F6 · ownership.nature: Consists of 3,557,377 shares held of record by APNG I and 7,961,823 shares held of record by Alta VIII. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 17:01 UTC | Allakos Inc. ALLK · Entity 79644 | ConversionCommon Stock | 11,269,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-043627 · doc4.xml · nonDerivative · entry 1 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,269,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2 · price: The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: Consists of 3,446,265 shares held of record by Alta Partners NextGen Fund I, L.P. ("APNG I") and 7,822,935 shares held of record by Alta Partners VIII, L.P. ("Alta VIII"). F4 · ownership.nature: The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. F5 · ownership.nature: The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC ("APNG I Management"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their pecuniary interests therein. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 21:43 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $15.08 | $0.00 |
DisclosureSEC source: 0001562180-18-002850 · primarydocument.xml · derivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-01 F1 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. Read SEC document |
| March 29, 2018 Filed Mar 29, 2018 20:50 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 14,429 | $18.78 | $270,976.62 |
DisclosureSEC source: 0001140361-18-016002 · doc1.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,820 F2 · price: This transaction was executed in multiple trades in prices ranging from $18.75 to $18.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 28, 2018 Filed Mar 29, 2018 20:50 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 10,000 | $18.84 | $188,400.00 |
DisclosureSEC source: 0001140361-18-016002 · doc1.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,249 F1 · price: This transaction was executed in multiple trades in prices ranging from $18.8213 to $18.869, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:24 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionSeries A-3 Preferred Stock · Derivative | 32,892 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029597 · doc1.xml · derivative · entry 4 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,892 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:24 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionSeries A-2 Preferred Stock · Derivative | 136,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029597 · doc1.xml · derivative · entry 3 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 136,286 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:24 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionCommon Stock | 32,892 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029597 · doc1.xml · nonDerivative · entry 2 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:24 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionCommon Stock | 136,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029597 · doc1.xml · nonDerivative · entry 1 MORE ROBERT J · CIK 0001207792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.